ES2189165T3 - Nuevos compuestos macrociclicos como inhibidores de metaloproteasa. - Google Patents

Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.

Info

Publication number
ES2189165T3
ES2189165T3 ES98921183T ES98921183T ES2189165T3 ES 2189165 T3 ES2189165 T3 ES 2189165T3 ES 98921183 T ES98921183 T ES 98921183T ES 98921183 T ES98921183 T ES 98921183T ES 2189165 T3 ES2189165 T3 ES 2189165T3
Authority
ES
Spain
Prior art keywords
compounds
inhibitors
metaloproteasa
macrociclic
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98921183T
Other languages
English (en)
Inventor
Chu-Bio Xue
Carl P Decicco
Robert J Cherney
Elizabeth Arner
William F Degrado
Jingwu Duan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ES2189165T3 publication Critical patent/ES2189165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)

Abstract

Un compuesto, y una de sus formas de sal farmacéuticamente aceptable, seleccionado de: 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[glicina - n - pentil éster] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 4 - fenil - 1 - butilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[5 - metoxitriptamina] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[1 - (2, 5 - dimetoxifenil) - 2 - glicina - amidoetanol] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[glicina - t - butil éster] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[ácido L - glutámico - a, g - di - t - butil éster] -ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[glicina] - ciclopentadecano - 13 N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 2 - fenil - 1 - butilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[2 - (2 - aminoetil) - 1 - metilpirrol] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[2 - (2 - aminoetil)bencenosulfonamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - ácido glutámico - g - ciclohexil éster - N - metil amida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - fenilalanina - p - fluoro - N metilamida] - ciclopentadecano - 13 - N - hidrixicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - fenilalanina - p - metoxi - N (S) - a - metilbencilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - ciclohexilmetil amida] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 3 - fenil - 1 - propil - amida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 3, 3 - difenilpropil amida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - (2 - aminoetilamino)etil pirrolidina] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - 3(2¿ - nafti1)alanina - N - metil amida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[etil - 4 - amino - 1 - piperidina carboxilato] - ciclopentade cano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[5 - metil - triptamina] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 4 - trifluorometilbencil amida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - ácido glutámico] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[2 - (dietilamino)etil - 4 - amino benzoato] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[6 - fluorotriptamina] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 -isobutil - 2[6 - metoxi triptamina] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[triptamina] - ciclopentadecano 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - metilpiperazinamida)carboxamida] - ciclo - pentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - alanina - N - morfolinamida)carboxamida] - ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - valina - N - morfolinamida)carboxamida] - ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - terc - butilglicina - N morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (b - alanina - N - morfolinamida)carboxamida] - ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (etoxicarbonil - N - morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (2 - hidroxi - 2 - feniletil)carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 3S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - bencilpiperazinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - fenilpiperazinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - (2 - piridil)piperazinamida)carboxamida] ciclopentadecano - 13 - N -hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (a - ciclopropanoetiloxicarboxamida - b - alanina) - carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - {N - [glicina - N - 4 - (1 - piperidinil)piperidinamida] - carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (R - isopropiloxicarbonil N - morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (S - isopropiloxicarbonil N - morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (2 - tiazol - 4 - ácido acético)carboxamida]ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo- 9 - oxa - 14 - isobutil - 2 - [N - (a - ciclopropanoetiloxicarboxamida - b - alanina - N - dimetilamida)carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (a - ciclopropanoetiloxicarboxamida - b - alanina - N - morfolinamida)carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (2 - tiazol - 4 - acetil - N morfolinamida)carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - serina - N - morfolinamida)carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - piperidinamida - 3 - ácido carboxílico) - carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 2, 6 - dimetilmorfolinamida)carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - etoxicarbonilpiperazinamida) - carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - etoxicarbonilpiperidinamida) carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - {N - [4 - (1 morfolinil)fenil]carboxamida}ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - {N - [glicina - N - (4 - (1 - morfolinil)anilida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - piperidinamida - 4 - ácido carboxílico) - carboxamida] -ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - metilcarboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [alanina - N - metilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [metilcarboxi] - ciclopentadecano 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [glicina - N - metilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [2 - N - morfolinoetilcarboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [3 - N - morfolinopropilcarboxamida] - ciclopentadecano - 13 - N - hidroxicarbox
ES98921183T 1997-05-14 1998-05-14 Nuevos compuestos macrociclicos como inhibidores de metaloproteasa. Expired - Lifetime ES2189165T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/856,223 US6281352B1 (en) 1995-11-14 1997-05-14 Macrocyclic compounds as metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
ES2189165T3 true ES2189165T3 (es) 2003-07-01

Family

ID=25323094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98921183T Expired - Lifetime ES2189165T3 (es) 1997-05-14 1998-05-14 Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.

Country Status (9)

Country Link
US (1) US6281352B1 (es)
EP (1) EP0981521B1 (es)
JP (1) JP2001524949A (es)
AT (1) ATE229514T1 (es)
AU (1) AU7385398A (es)
CA (1) CA2287923A1 (es)
DE (1) DE69810100T2 (es)
ES (1) ES2189165T3 (es)
WO (1) WO1998051665A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
US6649377B1 (en) 1999-05-10 2003-11-18 Syntex (U.S.A.) Llc Human aggrecanase and nucleic acid compositions encoding the same
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
AU2002238939A1 (en) * 2002-03-18 2003-09-29 Nihon University Cyclic etheramine derivatives as medicaments for malignant tumors
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
CA2528375C (en) 2003-06-18 2013-11-19 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US20090182019A1 (en) * 2005-04-18 2009-07-16 The Johns Hopkins University Histone deacetylase inhibitors
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2017177144A1 (en) * 2016-04-08 2017-10-12 Yale University Novel matrix metalloproteinase inhibitors and imaging agents, and methods using same
CA3115038A1 (en) 2018-10-04 2020-04-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Egfr inhibitors for treating keratodermas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
EP0586537A4 (en) 1991-05-28 1997-06-25 Merck & Co Inc Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5427954A (en) 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
SK63498A3 (en) 1995-11-14 1999-01-11 Du Pont Merck Pharma Novel macrocyclic compounds as metalloprotease inhibitors

Also Published As

Publication number Publication date
EP0981521B1 (en) 2002-12-11
DE69810100D1 (de) 2003-01-23
WO1998051665A3 (en) 1999-03-25
JP2001524949A (ja) 2001-12-04
ATE229514T1 (de) 2002-12-15
CA2287923A1 (en) 1998-11-19
AU7385398A (en) 1998-12-08
US6281352B1 (en) 2001-08-28
WO1998051665A2 (en) 1998-11-19
EP0981521A2 (en) 2000-03-01
DE69810100T2 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
DE69838070D1 (de) Substituierte pyridin-derivate als entzündungshemmende mittel
DK1448564T3 (da) Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
YU64701A (sh) Jedinjenja upotrebljiva kao anti-inflamatorna sredstva
BR9916930A (pt) Compostos heterocìclicos aromáticos comoagentes antiinflamatórios
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE69810100D1 (de) Macrocyclische verbindungen als metallproteaseinhibitoren
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение